For Alzheimer's patients, a new era of treatment brings hope and risk

A drug called Leqembi, which modestly slows progression of the disease, is expected soon to receive full approval from federal regulators.

Related Keywords

University Of The Pacific ,California ,United States ,Kansas ,Tokyo ,Japan ,Fayetteville ,North Carolina ,Stockton ,Colorado Springs ,Colorado ,Cambridge ,Cambridgeshire ,United Kingdom ,Duke University ,University Of Kansas ,Boston ,Massachusetts ,Americans ,Howard Fillit ,Eli Lilly ,Allan Levey ,Jay Reinstein ,Mel Brooks ,Reisa Sperling ,R Scott Turner ,Thomasm Wisniewski ,Jeffreym Burns ,Davids Knopman ,Gil Rabinovici ,Kenneth Covinsky ,Larry David ,Lois Reinstein ,Drug Administration ,Aetna ,University Of Kansas Is Steve Grant ,Alzheimer Drug Discovery Foundation ,Langone Health ,Emory University School Of Medicine ,Centers For Disease ,University Of California At San Francisco ,Medstar Georgetown University Hospital ,Alzheimer Association ,Georgetown University School Of Medicine ,Medstar Georgetown University ,Emory University School ,Mayo Clinic ,Steve Grant ,Joanna Fix ,Drug Discovery Foundation ,African Americans ,Georgetown University School ,Social Security ,Medicare Advantage ,Disease Control ,Memory Disorders Clinic ,Duke University Health Systems ,Ella Fitzgerald ,Cindy Beam ,